drugset
drugset / Trial / NCT02873598

A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

NCT02873598 ↗

Phase 1 Completed 14 enrolled University of Colorado, Denver
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy (FOLFIRINOX or gemcitabine and nab-paclitaxel).

Timeline

Start
2016-11-17
Primary completion
2019-06-07
Completion
2022-11-28

Drugs

EvaluationDrugModalityDoseRoute
Background Abraxane Small molecule — —
Background Gemcitabine Small molecule — —

Indications

malignant pancreatic neoplasm